cell-type determination in a variety of tissues and organs. 6 Recently, the OLIG genes have been identified and belong to the family of bHLH transcription factors. In fact, they could be specific to the oligodendrocyte lineage. 10, 22 Results of Northern blot analysis showed that the OLIG1 and OLIG2 transcripts were specific to the brain in the rat. Further, OLIG1 and OLIG2 gene expression was also found in O-2A cells in dissociated primary cultures of P5 rat optic nerve. In developing mouse embryos, OLIG1 and OLIG2 genes were expressed in OPCs in the ventral spinal cord. Their expression preceded that of PDGFR␣ and persisted in the adult rat stage. Other authors have shown that OLIG2 is expressed by a progenitor common to neurons and oligodendrocytes in the mouse. 18 Very recently, OLIG genes in humans have been reported to be reliable markers of oligodendrogliomas. 9, 11 In these studies the expression of OLIG genes were analyzed using in situ hybridization in a limited number of gliomas.
To characterize further the histogenesis of gliomas in the human brain and to define specific markers for diagnosis, we have used semiquantitative RT-PCR to search for the expression of human orthologs of OLIG genes in normal adult and fetal brain tissues and in 89 CNS tumors. Particular attention was paid to the subgroup of pilocytic astrocytomas, which shared with O-2A cells the expression of some molecules. 5, 17 In a few cases, dot blot and in situ hybridization were also performed to confirm further the quantification demonstrated in RT-PCR analysis and to see the cellular pattern of expression of the OLIG2 gene. We show that OLIG1 and OLIG2 genes in humans are expressed in glial tumors only and that the level of expression varies according to the pathological diagnosis.
Materials and Methods

Human Tissue Collection
The present study was undertaken after informed consent was obtained from each patient or the patient's relatives.
Brain tumor samples were collected in the operating room. All tumors were classified by three pathologists according to the World Health Organization CNS tumor classification. 8 They included 10 pilocytic astrocytomas, four Grade II astrocytomas, three Grade III anaplastic astrocytomas, 19 Grade IV glioblastomas, 15 Grade II oligodendrogliomas, and 20 Grade III anaplastic oligodendrogliomas. In addition, eight ependymomas were studied. Control tumors included four meningiomas, three schwannomas, and three medulloblastomas.
Brain (frontal lobe) tissues were obtained during autopsies in two adults who had died from nonneurological disorders and in two fetuses (14 and 20 weeks of gestation) that had spontaneously terminated. These tissues were obtained less than 12 hours after death. Neuropathological examination was normal in all cases. Samples were placed in liquid nitrogen and stored at Ϫ80˚C until the extraction of RNA.
For in situ hybridization, one additional specimen from two pilocytic astrocytomas and two oligodendrogliomas were fixed in 2% paraformaldehyde for 4 hours, cryoprotected in phosphate-buffered saline containing 20% sucrose overnight, and then frozen in melting isopentane and stored at Ϫ80˚C.
Experimental Procedures
Extraction of RNA and RT. Total cellular RNA was extracted using the guanidinium thiocyanate method, 2 followed by the addition of deoxyribonuclease I (20 U/sample) and RNAsin (40 U/sample) for 15 minutes at 37˚C. Reverse transcription was performed on approximately 1 g total RNA by using hexanucleotide random primers (Boehringer, Meylan, France) and reverse transcriptase (SuperScript; Life technologies, Cergy Pontoise, France), according to the recommendations of the manufacturers.
Detection of the GAPDH Transcript in the Different Tissues. First, relative RT-PCR amplification of the GAPDH transcripts was performed on a PCR express gradient cycler (Hybaid; Coger, Paris, France) to confirm RNA integrity and to homogenize the amount of cDNA to be used in each of the PCRs. A limited number of cycles were used, and this allowed us to focus on the linear portion of the amplification curve. Intensity analysis of the amplified bands was performed with an imager (Appligene, Illkinch, France) and the appropriate computer program (Imager, version 1.61; Natural Institutes of Health, Bethesda, MD). The volume of RT reactions (or the amount of cDNA) was then adjusted to obtain equal amounts of GAPDH amplification product for each case. 1 The GAPDH primers used are described in Table 1 , and we adhered to the following program for 22 cycles: 1) denaturation at 95˚C for 10 seconds; 2) annealing at 65˚C for 15 seconds; and 3) DNA synthesis at 72˚C for 8 seconds.
Detection of OLIG1 and OLIG2 mRNAs in Different Tissues. In a second step, amplification of the OLIG1 and OLIG2 mRNAs was performed with an equal amount of cDNA, 200 ng of each specific primer, 200 mM deoxynucleoside triphosphate and 2.5 U Taq DNA polymerase in a solution of 10 mM Tris-HCl, 50 mM KCl, and 1.5 mM MgCl 2 (pH 8.3) supplemented with Q solution (Qiagen, Courtaboeuf, France) at a final concentration ϫ 1. The primers used are described in Table 1 .
Polymerase chain reaction amplification was performed as follows: for OLIG1, 31 cycles of denaturation at 95˚C for 40 seconds, annealing at 57˚C for 40 seconds, and DNA synthesis at 72˚C for 40 seconds; for OLIG2, 30 cycles of denaturation at 95˚C for 50 seconds, annealing at 60˚C for 40 seconds, and DNA synthesis at 72˚C for 40 seconds. Controls included samples lacking cDNA as template, and RT reactions were performed without reverse transcriptase. The OLIG1 and OLIG2 PCR amplification products (379 and 432 bp, respectively) were purified (Geneclean; Bio 110, Illkirch, France), subcloned into a pGEM-T vector (Promega, Lyon, France), and sequenced to verify specific amplification.
Ten microliters of PCR products was subjected to electrophoresis on a 2% agarose gel (Eurobio, les Ullis, France) in a 1 ϫ Tris base/ acetate/EDTA buffer. Intensity analysis of the amplified products was performed as described earlier and expressed in arbitrary units. This procedure was performed twice.
Quantitative Analysis of OLIG2 mRNA by Dot Blot Hybridization.
Sequential dilutions of total RNA from two pilocytic astrocytomas and two oligodendrogliomas (one Grade II and one Grade III) and from fetal brain tissue were spotted onto nitrocellulose membranes by using a manifold apparatus (Minifold I; Schleicher & Schuell, Inc., Ecquevilly, France). For hybridization with OLIG2 and GAPDH probes the dilutions were 10:0.078 g for the samples test- ed. After spotting, the filters were baked for 2 hours at 80˚C before hybridization. Prehybridization was performed at 42˚C for 4 hours in 50% formamide, 5 ϫ standard sodium phosphate EDTA, and 5 ϫ Denhardt solution containing 250 g/ml denatured salmon sperm DNA. Hybridization was conducted for 24 hours at 42˚C in the earlier-mentioned solution by using 1 ϫ, instead of 5 ϫ, Denhardt solution and supplied with an [␣-32 P]deoxycytidine triphosphate probe. Washes were performed twice with a 2 ϫ standard saline citrate-0.1% sodium dodecyl sulfate solution for 5 minutes and twice with a 0.1 ϫ standard saline citrate-0.1% sodium dodecyl sulfate solution for 30 minutes each time at 50˚C. Messenger RNA concentrations were estimated from the slopes of the linear regression curves of the dots after scanning the autoradiographs at 490 nm with the aid of an optical densitometer (MR 5000; Dynatech Corp., Chantilly, VA). Differences in total RNA loading were eliminated by normalization with the quantification of the GAPDH mRNA. Results were calculated as the OLIG2/GAPDH ratio.
In Situ Hybridization Analysis of OLIG2 Expression. Only OLIG2 expression was investigated by performing in situ hybridization on cryostat sections of 10 m with a digoxigenin-labeled cRNA antisense probe, according to the procedure previously reported. 11 The cRNA probe was detected with an alkaline phosphatase-conjugated antibody against digoxigenin and visualized by incubation in 4-nitro blue tetrazolium chloride/5-bromo, 4-chloro, 3-indolyl phosphate for 12 hours.
Statistical Analysis
Appropriate statistical tests (Kruskal-Wallis test or Mann-Whitney U-test) were performed to compare OLIG gene expression in the different groups of tumors.
Results
Data regarding semiquantitative RT-PCR for OLIG genes are provided in Table 2 and presented in graphic form in Figs. 1 and 2 .
Expression of OLIG1 and OLIG2 in Normal Brain and Primary CNS Tumors
Expression of the OLIG genes was observed in all nor- mal frontal lobe samples studied and was higher in the fetal brain compared with that in the adult brain (Fig. 3) .
Under defined PCR conditions OLIG1 and OLIG2 gene expression was detected in most gliomas (Fig. 3 ). In contrast, however, one Grade III astrocytoma demonstrated neither gene and another demonstrated only OLIG1. Five glioblastomas and three Grade III oligodendrogliomas demonstrated neither gene. Three other Grade III oligodendrogliomas demonstrated OLIG1 only. Ependymomas showed a very low level of expression, whereas medulloblastomas, schwannomas, and meningiomas had no detectable value of OLIG gene expression. Therefore, OLIG gene expression was significantly different between gliomas and other primary CNS tumors (ependymomas and nonneuroepithelial tumors; p Ͻ 0.001).
Expression of OLIG Genes Varied According to Glioma Subtype
Expression of OLIG Genes Based on RT-PCR. Pilocytic astrocytomas always expressed OLIG genes and usually exhibited the highest level of expression on RT-PCR, although one patient had low OLIG1 and OLIG2 gene expression. Although we have no definitive explanation for this result, it is worth noting that this tumor was located in the brainstem of a 22-year-old woman. Other locations for pilocytic astrocytomas included in our series were the posterior fossa (six cases) and medulla (three cases). They tended to occur in younger patients.
Because the differential diagnosis between pilocytic astrocytomas and diffuse gliomas is sometimes difficult, we have compared OLIG gene expression in pilocytic astrocytomas with other gliomas by using appropriate statistical tests ( Table 3 ). The expression of the OLIG gene in pilocytic astrocytomas was significantly different from that in diffuse gliomas (p = 0.003 for OLIG1, p Ͻ 0.001 for OLIG2). In addition, OLIG gene expression was also higher in pilocytic astrocytomas compared with that in diffuse astrocytomas (p = 0.002 for OLIG1, p = 0.001 for OLIG2), oligodendrogliomas (p = 0.011 for OLIG1, p = 0.001 for OLIG2), or compared with glioblastomas (p = 0.002 for OLIG1, p = 0.001 for OLIG2).
Among diffuse gliomas, OLIG gene expression was not statistically different between astrocytomas and oligodendrogliomas and it did not vary according to grade. Results of statistical analysis are provided in Table 3 .
Dot Blot Analysis of OLIG2 Gene Expression. Quantitative analysis of mRNA for OLIG2 by dot blot hybridization showed an equal amount of OLIG2 mRNA when comparing mean values achieved for the two cases of pilocytic astrocytomas and the two cases of oligodendrogliomas. The expression of OLIG2 was sixfold higher in tumors compared with fetal brain tissue (Fig. 4) . It is worth noticing that in this dot blot hybridization experiment, the total amount of OLIG2 gene was almost identical in the two pilocytic astrocytomas and oligodendrogliomas regardless of tumor grade.
Cellular Pattern of OLIG2 Gene Expression. Results of in situ hybridization showed that almost all tumor cells in a pilocytic astrocytoma as well as those in the two oligodendrogliomas tested demonstrated cytoplasmic staining with cRNA antisense OLIG2 probe (Fig. 5) . Note, however, that the total amount of OLIG2 gene expression was strong in every tumor cell in pilocytic astrocytomas (Fig. 5A and B) and Grade II oligodendrogliomas (Fig. 5C and D) and that its expression was different from one tumor cell to another in Grade III oligodendrogliomas (Fig. 5E and F 
Discussion
The recent discovery of OLIG genes in OPCs and mature oligodendrocytes 9, 10, 18, 21, 22 prompted us to study the expression of these genes in normal human brain tissue and primary CNS tumors to search for a selective marker of oligodendrogliomas. Our results confirm to some extent and in a larger number of tumors the data from two recent studies, 9, 11 showing OLIG gene expression in normal human brain tissue and in gliomas. Furthermore, our data revealed (for the first time) expression of OLIG genes in pilocytic astrocytomas.
Expression of OLIG Genes in Normal Human Brain Tissue
Although both genes were expressed in fetal and adult human frontal lobe tissue, their expression was higher in fetal brain. The OLIG genes are expressed in the OPCs, which are abundant in the developing brain and are still present and located in specific areas of the adult CNS (for example, corpus callosum and cerebellar white matter). These areas were not included in the specimens examined because our study was restricted to frontal lobe tissue. This could explain the low level of OLIG genes in adult human brain tissue previously reported by others. 9 
Expression of the OLIG Gene is Restricted to Glial Neoplasms
The OLIG genes were expressed only in gliomas (pilocytic astrocytomas and diffuse gliomas) and at very low levels in ependymomas. Because their normal counterparts (meningothelial cells and Schwann cells) do not express these genes, the absence of OLIG gene expression in meningiomas and schwannomas is not surprising. The OLIG genes were not observed by Zhou, et al., 22 in meningeal cells and developing Schwann cells or their precursors. In addition, we did not observe OLIG gene expression in medulloblastomas, although the number of cases studied was too low to offer any insight into the histogenesis of this tumor-which is still a matter of debate. 15 
Expression of the OLIG Gene Varies According to the Glioma Subtype
In contrast to data from other recent studies, 9,11 OLIG gene expression was not restricted to oligodendrogliomas but was recorded in all glial tumors we tested using semiquantitative RT-PCR. This might be explained in several ways. 1) The number of cases studied was much lower than the number of cases included in the present series, a possible indication of selection bias. For example, it is clear that some glioblastomas might express OLIG genes: two of eight lesions in the study by Lu, et al., 9 and 12 of 19 lesions in our study. 2) The difference observed in the data can be explained by the method used. Polymerase chain reaction is a much more sensitive method and although we have shown a good correlation between the level of OLIG2 gene expression by semiquantitative RT-PCR and dot blot analysis in some cases, it is clear that quantitative RT-PCR cannot distinguish between the diffuse, low level of OLIG gene expression by all tumor cells in a highly dense tumor (likely the case in most glioblastomas) and the strong expression of the OLIG gene by scattered tumor cells.
Except for one case, OLIG gene expression was high in pilocytic astrocytomas. Results of dot blot analysis further confirm the high expression of OLIG2 in these gliomas, and in situ hybridization showed that tumor cells did express the OLIG2 gene. Such results corroborate recent findings that pilocytic astrocytomas express some markers of OPCs such as NG2 chondroitin sulfate proteoglycan, PDGFR␣, and PEN5. 5, 17 Coexpression of PDGFR␣ and NG2 characterize OPCs. Moreover, by using different markers we have demonstrated that the PEN5 epitope (which is a sulfated polylactosamine carbohydrate epitope first described in a subpopulation of mature natural killer cells 20 ) identifies OPCs at the transient intermediate stage between the A2B5ϩ/ GalcϪ and A2B5Ϫ/Galcϩ and marks the transition from the proliferative to the postmitotic stage. Expression of the OLIG gene in the developing spinal cord precedes PDGFR␣ and then is coexpressed with PDGFR␣ in both the spinal cord and all areas of presumptive migrating oligodendrocyte precursors. 10, 18 Taken together, these data indicate that pilocytic astrocytomas share with OPCs the same markers from the earliest OLIG genes to the presumed latest, that is, PEN5. Results of other studies have shown that antigens present during the oligodendrocyte lineage in vitro, such as PDGFR␣ and A2B5, are variably expressed in gliomas. 7 Other authors also found both NG2 and PDGFR␣ expression 17 in a subset of glioblastomas, although these tumors do not express PEN5. 5 Altogether, these results indicate that all glial tumors may arise from OPCs. As previously suggested it is likely that OPCs, which are present in the adult human brain, 12, 16 have the potential to produce to neoplasms with distinctive clinical and pathological phenotypes, perhaps as a result of different environmental influences within the brain parenchyma or different genetic alterations.
Conclusions
In this study we have reported that OLIG genes are expressed in gliomas, with their highest expression in pilocytic astrocytomas. Results of statistical analysis showed that OLIG gene expression by semiquantitative RT-PCR did not vary according to tumor grade in the subgroup of oligodendrogliomas. The OLIG genes represent new markers of gliomas and, when possible, immunohistochemical analysis of formalin-fixed paraffin-embedded specimens would be the most simple and accurate method of investigating OLIG gene expression and assessing its putative prognosis value in gliomas. It is likely that the study of various markers of OPCs and relevant genetic information, such as 1p and 19q status, may help to classify gliomas. Finally, a better understanding of factors controlling commitment, proliferation, survival, and differentiation of OPCs will help the identification of new therapies in patients with gliomas.
